James Collins, MD
Neurology with Special Qualifications in Child Neurology · Branson, MONPI 1811105331
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $431, 2.5 times the $174 reported in 2019.
Across 61 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$386
- Boston Scientific$350
- Jazz Pharmaceuticals Inc.$171
- SK Life Science, Inc.$122
- UCB, Inc.$92
- Ipsen Biopharmaceuticals, Inc$81
- plus $421 from 15 others
What the payments were for
- Food & beverage$1,622100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 22 | $386 |
| Boston Scientific | 5 | $350 |
| Jazz Pharmaceuticals Inc. | 4 | $171 |
| SK Life Science, Inc. | 1 | $122 |
| UCB, Inc. | 3 | $92 |
| Ipsen Biopharmaceuticals, Inc | 4 | $81 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
| Merck | 3 | $51 |
| Catalyst Pharmaceuticals, Inc. | 2 | $45 |
| Ascendis Pharma Endocrinology Inc | 2 | $43 |
| Dexcom, Inc. | 2 | $40 |
| Corium, LLC | 1 | $30 |
| Zogenix Inc. | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| QOL Medical, LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Neurelis, Inc. | 1 | $17 |
| NS Pharma, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Sarepta Therapeutics, Inc. | 1 | $14 |
| Livanova USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$124
- XCOPRI$122
- GENERAL ENDOCHOICE$100
How this compares
$1,622 in reported general payments places this provider in the 70th percentile of 41 neurology with special qualifications in child neurology providers in Missouri.
See all neurology with special qualifications in child neurology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Branson
- Ahmed AbdelmoityKansas City$1.1M
- Nico DosenbachSaint Louis$132K
- Craig ZaidmanSaint Louis$110K
- Dusit AdstamongkonkulSpringfield$9K
- Deron SharpeColumbia$8K
- Brian AalbersKansas City$6K
- Liu ThioSaint Louis$6K
- Bhooma AravamuthanSaint Louis$4K
- Zhao LiuColumbia$3K
- Mirza Waseem BaigKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.